13,14-dihydro-15-keto-PGE2,
13,14-dihydro-15-ketoprostaglandin E2,
15-keto-13,14-dihydro-PGE2,
15-keto-13,14-dihydroprostaglandin E2,
15-keto-13,14-dihydroprostaglandin E2, (11alpha)-isomer,
PGEM (13,14-dihydro-15-keto-PGE2),
13,14-Dihydro-15-keto-PGE2,
PGEM,
363-23-5,
15-Keto-13,14-dihydro-PGE2,
15-keto-13,14-dihydroprostaglandin E2,
13,14-Dihydro-15-ketoprostaglandin E2,
KH(2)PGE(2),
13,14-dihydro-15-keto Prostaglandin E2,
9,15-dioxo-11R-hydroxy-5Z-prostenoic acid,
PGE2 13,14-dihydro,
13,14-dihydro-15-oxo-prostaglandin E2,
(5Z)-(15S)-11alpha-Hydroxy-9,15-dioxoprostanoate,
dhk-PGE2,
AC1NQXGW,
(5Z)-11alpha-hydroxy-9,15-dioxoprost-5-enoic acid,
SCHEMBL13958223,
BDBM82093,
CHEBI:15550,
CUJMXIQZWPZMNQ-XYYGWQPLSA-N,
HMS3648H15,
PGE2, 13,14-dihydro15-oxo,
13,14-Dihydro-15-keto PGE2,
1191AH,
LMFA03010031,
ZINC12496032,
CAS_363-23-5,
13,14-dihydro-15-keto-Prostaglandin E2,
11-alpha-hydroxy-9,15-dioxoprost-5-enoate,
13,14-dihydro-15-keto Prostaglandin E2-d4,
C04671,
11-alpha-hydroxy-9,15-dioxoprost-5-enoic acid,
13,14-Dihydro-15-ketoprostaglandin E2 solution,
SR-01000946429,
SR-01000946429-1,
13,14-Dihydro-15-ketoprostaglandin E2 solution, ~90%,
Prost-5-en-1-oic acid, 11-hydroxy-9,15-dioxo-, (5Z,11alpha)-,
(Z)-7-[(1R,2R,3R)-3-hydroxy-5-oxo-2-(3-oxooctyl)cyclopentyl]hept-5-enoic acid,
FA(20:1(OH,Ke2,cyclo)),
C20H32O5,
CID5280711,
PGEM (13,14-dihydro-15-keto-PGE2),
13,14-DIHYDRO-15-KETOPROSTAGLANDINE2,
C025087,
15-keto-13,14-dihydroprostaglandin E2, (11alpha)-isomer,
prost-5-en-1-oic acid, 11-hydroxy-9,15-dioxo-, (5Z,11 alpha)-,